These findings have shown that keratinocyte cell death is a potent trigger of skin inflammation and highlight the pro-inflammatory risk of using inhibitors that target cell survival signalling pathways (e.g. LUBAC or IKK2 inhibitors) for treatment of CARD14-dependent psoriasis. Here, IKBKB is linked to dermatitis.